Authors

Mark A. Socinski, MD, University of Pittsburgh

Mark A. Socinski, MD, University of Pittsburgh Medical Center

Mark A. Socinski, MD, UPMC

Mark Agulnik, MD, Feinberg School of Medicine

Mark Agulnik, MD, Northwestern University Feinberg School of Medicine

Mark Anderson

Latest:

Overcoming the Hurdles to EHR Adoption

A survey conducted by the Institute for Health Policy between late 2007 and early 2008 found that only 4% of physicians are using a fully functional EHR.

Mark B. Juckett, MD

Latest:

Dr Juckett on the Evolving Treatment Paradigm in Relapsed/Refractory AML

Mark Juckett, MD, discusses ways the treatment paradigm has changed for patients with relapsed/refractory acute myeloid leukemia.

Mark Ball, MD

Latest:

Dr. Ball on Eventual Role of Immunotherapy in Patients With RCC

Mark Ball, MD, chief urology resident, Johns Hopkins University School of Medicine, discusses the eventual role that immunotherapy will play in the treatment landscape of renal cell carcinoma (RCC), as well as patient selection to receive immunotherapy as a single agent or in combination.

Mark Burkard, MD, PhD

Latest:

What Can We Learn From "Extreme Survivors" of Breast Cancer?

Mark Burkard, MD, PhD, discusses an unusual study launched at the University of Wisconsin.

Mark C. Scholz, MD

Latest:

Dr. Mark Scholz on Advances in Prostate Cancer Imaging

Mark C. Scholz, MD, from Prostate Oncology Specialists Inc, describes his excitement over advances in prostate cancer imaging techniques, specifically those involving multiparametric MRI.

Mark D. Duncan, MD

Latest:

Dr. Duncan on Measuring the Success of Patient Navigation

Mark D. Duncan, MD, from The Johns Hopkins University School of Medicine, discusses demonstrable metrics that help measure the success of a patient navigation program.

Mark D. Peg

Mark D. Pegra

Mark D. Pegram, MD

Latest:

Looking Ahead: Expert Future Perspectives in the HR+ Breast Cancer Landscape

A panel of experts offer future perspectives in HR+ breast cancer.

Mark D. Tyson, MD

Latest:

Dr Tyson on the Phase 3 BOND-003 Trial in BCG-Unresponsive NMIBC With CIS

Mark D. Tyson, II, MD, MPH, discusses findings from the phase 3 BOND-003 trial in BCG-unresponsive non–muscle-invasive bladder cancer with CIS.

Mark Delworth, MD

Latest:

Dr. Mark Delworth on Robotic Prostatectomy

Mark Delworth, MD, a urologist and the medical director of the Minimally Invasive and Robotic Surgery Program at TriHealth Hospital, talks about the outcomes of robotic surgery for the treatment of prostate cancer.

Mark E. Robson, MD

Latest:

Dr. Robson on the Potential Utility of Tucatinib in HER2+ Breast Cancer

Mark E. Robson, MD, discusses the potential utility of tucatinib in the treatment of patients with HER2-positive breast cancer.

Mark E. Robson, MD, Memorial Sloan Kettering Cancer Center

Latest:

Operational Processes and Challenges

Mark Robson, MD; John Henson, MD; Ashley Ross, MD, PhD; and Dana Farengo Clark, MS, LCGC, discuss operational processes and techniques for counseling patients about germline testing.

Mark Emberton, MD

Latest:

Dr. Emberton on Focal Therapy Techniques in Prostate Cancer

Mark Emberton, MD, professor of Interventional Oncology, Division of Surgery and Interventional Science, University College London Hospitals, clinical director, Clinical Effectiveness Unit, Royal College of Surgeons of England, discusses techniques of focal therapy in patients with prostate cancer.

Mark Emberton, MD, FRCS

Latest:

Dr. Emberton on the Importance of Multidisciplinary Care in Prostate Cancer

Mark Emberton, MD, FRCS, professor, Interventional Oncology, Division of Surgery and Interventional Science, University College London, clinical director, Clinical Effectiveness Unit, Royal College of Surgeons of England, discusses the importance of a multidisciplinary approach to the treatment of patients with localized prostate cancer.